Clinical Trial Update: SPIRIT II: A Clinical Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial (SPIRIT II) evaluating the XIENCE V Everolimus-eluting coronary stent system has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease
• Coronary Restenosis

Drugs mentioned

• XIENCE V Everolimus Eluting Coronary Stent System (Everolimus-eluting coronary stent)

Snippet

Sponsor: Abbott Medical Devices | Conditions: Coronary Disease, Coronary Artery Disease | Phase 3 | Status: COMPLETED